23643-61-0

Basic information

• Product Name: ardisiacrispin A
• Synonyms: ardisiacrispin A;DeglucocyclaMin I;Saxifragifolin B;Deglucocyclamin;LTS 4
• CAS NO: 23643-61-0
• Molecular Formula: C₅₂H₈₄O₂₂
• Molecular Weight: 1061.21016
• Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;reagent;standard substance
• Mol File: 23643-61-0.mol
• Article Data: 0

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.48±0.1 g/cm3 (20 ºC 760 Torr)
• PKA: 12.78±0.70(Predicted)
• CAS DataBase Reference: ardisiacrispin A(CAS DataBase Reference)
• NIST Chemistry Reference: ardisiacrispin A(23643-61-0)
• EPA Substance Registry System: ardisiacrispin A(23643-61-0)

Safety Data

• Hazardous Substances Data: 23643-61-0(Hazardous Substances Data)

Usage

Description

Ardisiacrispin A is an oleanane-type triterpenoid saponin, a natural compound derived from plants, which has been found to exhibit moderate cytotoxicity against various human cancer cell lines. This characteristic makes it a potential candidate for further research and development in the field of cancer treatment.

Uses

Used in Anticancer Applications:
Ardisiacrispin A is used as a cytotoxic agent for its ability to inhibit the growth and proliferation of human cancer cell lines. Its moderate cytotoxicity suggests that it may have potential applications in the development of novel cancer treatments, particularly for those cancers where it has demonstrated effectiveness.
Used in Pharmaceutical Research:
Ardisiacrispin A is used as a research compound for further investigation into its anticancer properties and potential mechanisms of action. This may lead to the discovery of new therapeutic approaches or the development of more effective drug delivery systems to enhance its bioavailability and therapeutic outcomes.
Used in Drug Development:
Ardisiacrispin A is used as a starting point for the development of new pharmaceuticals, as its cytotoxic properties against cancer cells may be harnessed to create more targeted and effective treatments. This could involve the synthesis of new compounds based on the structure of ardisiacrispin A or the exploration of its potential synergistic effects when combined with other anticancer agents.

Downstream Products

• 105214-60-6 C₆₃H₁₀₆O₂₂ 
• 5172-35-0 cyclamiretin D 
• 5172-34-9 cyclamiretin A